Regular scientist at the CHU de Québec-Université Laval Research Center and full professor in the Department of Molecular Medicine at the Laval University Medical School. He is a renowned Canadian scientist who has contributed to the advancement and acceptance of major new scientific concepts. This work has demonstrated that the CNS is a highly immunologically active organ, with complex immune responses, mostly based on innate immune processes. Such responses implicate a continuum of heterogeneous cell types, both inside the CNS, in the periphery, and at their interface, the blood brain barrier (BBB). The goal here is to manipulate such a system to prevent and cure brain diseases. Canadian Research Chair in Neuroimmunology, Twice named Quebec laureate, Radio Canada and Le Soleil (2007 et 2013). Over 21 000 citations and H factor 81.

The immune system at the rescue of brain diseases

The inflammatory response in neurodegenerative diseases has often been linked to progressive neuronal damage. However, mounting evidence now suggests that CNS-resident microglia and circulating monocytes that differentiate into macrophages upon infiltrating the cerebral tissue may exert more beneficial effects on neurons than previously thought. The innate immune system in the brain exhibits a dual nature, as best exemplified by multiple sclerosis (MS) and Alzheimer’s disease (AD), which are often treated as being brain diseases with similar immune etiologies. In reality, they are rather “Yin and Yang” in that regard.

Thus, the role of the inflammatory response seems highly divergent between MS and AD. On the one hand, the marked and sustained activation of proinflammatory monocytic cells promotes demyelination and axonal loss in MS, but on the other hand, it is the anti-inflammatory (or inactivated) phenotype of these cells that allows CNS amyloid accumulation, neuronal dysfunction and memory decline in AD. This research program is focused on thoroughly unraveling the mechanistic details of the role of the innate immune system in the CNS, and how it can be tackled to exert neuroprotective actions.

Vision: A multidisciplinary approach, integrating innovative discoveries and technologies, to validate the concept of the neuroprotective properties of the innate immune system, to improve brain disease diagnosis and treatment.

Goals: Our main goals are to provide new biomarkers for diagnosis and to obtain proofs-of-concept that will lead to new treatments of brain diseases based on the neuroprotective functions of innate immunity.

Objectives: 1) To decipher the molecular and cellular mechanisms involved in the intimate control of different compartments of the brain innate immune system. 2) To identify new biomarkers from the analysis of subsets of circulating monocytes in preclinical models of MS and AD. 3) To use and develop complementary models and methods to understand how myeloid cells can be harnessed in exerting neuroprotective actions. 4) To validate new biomarkers and concepts of the beneficial role of the innate immune system in humans.

CHUL
2705, boulevard Laurier
T-4-50
Québec, Québec
Canada G1V 4G2
250 entries « 1 of 25 »

Laflamme N, Lace B, Thonta Setty S, Rioux N, Labrie Y, Droit A, Chrestian N, Rivest S

A Homozygous Deep Intronic Mutation Alters the Splicing of Nebulin Gene in a Patient With Nemaline Myopathy.

Journal Article

Front Neurol, 12 , 2021.

Abstract | Links:

Al-Onaizi MA, Thériault P, Lecordier S, Rivest S, ElAli A

fvEarly monocyte modulation by the non-erythropoietic peptide ARA 290 decelerates AD-like pathology progression.

Journal Article

Brain Behav Immun, 2021.

Abstract | Links:

Piec PA, Pons V, Rivest S

Triggering Innate Immune Receptors as New Therapies in Alzheimer's Disease and Multiple Sclerosis.

Journal Article

Cells, 10 (8), 2021.

Abstract | Links:

Pal M, Lace B, Labrie Y, Laflamme N, Rioux N, Setty ST, Dugas MA, Gosselin L, Droit A, Chrestian N, Rivest S

A founder mutation in the gene in families from Saguenay-Lac-St-Jean region affected by a pyridoxine-dependent epilepsy.

Journal Article

JIMD Rep, 59 (1), 2021.

Abstract | Links:

Pons V, Levesque P, Plante MM, Rivest S

Conditional genetic deletion of CSF1 receptor in microglia ameliorates the physiopathology of Alzheimer's disease.

Journal Article

Alzheimers Res Ther, 13 (1), 2021.

Abstract | Links:

Fani Maleki A, Cisbani G, Laflamme N, Prefontaine P, Plante MM, Baillargeon J, Rangachari M, Gosselin J, Rivest S

Correction to: Selective Immunomodulatory and Neuroprotective Effects of a NOD2 Receptor Agonist on Mouse Models of Multiple Sclerosis.

Journal Article

Neurotherapeutics, 18 (2), 2021.

| Links:

Fani Maleki A, Cisbani G, Laflamme N, Prefontaine P, Plante MM, Baillargeon J, Rangachari M, Gosselin J, Rivest S, Rivest S

Selective Immunomodulatory and Neuroprotective Effects of a NOD2 Receptor Agonist on Mouse Models of Multiple Sclerosis.

Journal Article

Neurotherapeutics, 18 (2), 2021.

Abstract | Links:

Cisbani G, Rivest S

Targeting innate immunity to protect and cure Alzheimer's disease: opportunities and pitfalls.

Journal Article

Mol Psychiatry, 2021.

Abstract | Links:

Cisbani G, Poggini S, Laflamme N, Pons V, Tremblay ME, Branchi I, Rivest S

The Intellicage system provides a reproducible and standardized method to assess behavioral changes in cuprizone-induced demyelination mouse model.

Journal Article

Behav Brain Res, 400 , 2021.

Abstract | Links:

Picher-Martel V, Labrie Y, Rivest S, Lace B, Chrestian N

Whole-exome sequencing identifies homozygous mutation in TTI2 in a child with primary microcephaly: a case report.

Journal Article

BMC Neurol, 20 (1), 2020.

Abstract | Links:

250 entries « 1 of 25 »
Signaler des ajouts ou des modifications

Active projects

  • Chaire de recherche du Canada en neuroimmunologie, from 2016-07-01 to 2023-06-30
  • Chercheur d'un jour, from 2021-01-01 to 2022-12-31
  • Programme de soutien aux organismes de recherche et d'innovation (MESI_CATALIS Volet 2 - Recherche clinique) , from 2020-04-23 to 2022-03-31
  • Soutenir les établissements dans l'augmentation de leur capacité en recherche - agir sur la phase de démarrage des projets, Phase 2, from 2020-04-01 to 2022-03-31
  • Therapeutic properties of innate immune cells and system for brain diseases., from 2015-07-01 to 2022-06-30

Recently finished projects

  • Aménagement du secteur préclinique du centre de recherche , from 2018-12-01 to 2020-03-31
  • Appui au développement de la capacité en études cliniques précoces, from 2018-04-01 to 2020-03-31
  • Développement de marqueurs génétiques de maladies rares., from 2016-02-11 to 2020-02-10
  • Neurophotonics Initiative, phase II, from 2015-10-01 to 2021-03-30
  • Role of NOD-like receptors in lung immune response against respiratory virus infection, from 2012-10-01 to 2021-02-23
  • Soutenir les établissements dans l'augmentation de leur capacité en recherche - agir sur la phase de démarrage des projets , from 2019-04-01 to 2021-03-31
Data provided by the Université Laval research projects registery